Australia markets open in 5 hours 57 minutes

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5600-0.0300 (-1.89%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5900
Open1.5700
Bid1.5400 x 200
Ask1.5700 x 200
Day's range1.5150 - 1.5850
52-week range1.1750 - 9.7200
Volume166,458
Avg. volume501,219
Market cap80.252M
Beta (5Y monthly)1.52
PE ratio (TTM)N/A
EPS (TTM)-1.3200
Earnings date07 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.20
  • Zacks

    Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher

    PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  • GlobeNewswire

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

    PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings. Jefferies

  • GlobeNewswire

    Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

    BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP5